Physician profile
Amber Hart
NPI 1881199321
$856.49
in general payments reported to CMS, 2019-2025
11 companies · $697 in 2025
The $697 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $159 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $243.81 | 2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $230.52 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Abbott Laboratories | $113.76 | 2024 | Cardiomems |
| Viatris Specialty LLC | $76.56 | 2025 | Yupelri |
| Verona Pharma, INC. | $41.03 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $39.55 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $30.30 | 2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $25.15 | 2025 | Opsynvi |
| Ani Pharmaceuticals, INC. | $22.29 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $18.58 | 2025 | Zepbound |
| Philips North America LLC | $14.94 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.